Edgewise Therapeutics joined PPMD to share more about Edgewise’s ongoing clinical trials, which aim to protect muscle in individuals living with Becker. This webinar features Edgewise’s Chief Scientific Officer and Chief Medical Officer, who shares two year results from the completed Phase 1 ARCH study in adults with Becker and more information about their current enrolling trial, GRAND CANYON, a phase 2 pivotal cohort for adults living with Becker.